Galectin Therapeutics Inc
(NASDAQ:GALT)
$1.92
0.02[1.05%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$1.90
-0.0200[-1.04%]
Open1.950Close1.920
Vol / Avg.35.767K / 47.629KMkt Cap114.398M
Day Range1.850 - 1.95052 Wk Range1.030 - 2.470

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$11.00

Consensus Price Target1

$11.00

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
10000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Galectin Therapeutics

All Ratings (5)

Upgrades (0)

Downgrades (0)

Initiations (0)

Q

What is the target price for Galectin Therapeutics (GALT)?

A

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galectin Therapeutics (GALT)?

A

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Q

Is the Analyst Rating Galectin Therapeutics (GALT) correct?

A

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.